LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories (NASDAQ: CBRX) initiated a 42-patient clinical study of its vaginally-administered lidocaine candidate, which the Company is developing to prevent and treat dysmenorrhea. This study will evaluate blood levels obtained by Columbia’s vaginally-administered lidocaine formulation at each of three dose strengths over multiple doses.
